Advertisement GeNOsys completes development contract with IriSys Pharmaceuticals - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

GeNOsys completes development contract with IriSys Pharmaceuticals

GeNOsys, a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, has announced the completion of the company's nitric oxide generator portable tablet.

According to the company, IriSys successfully formulated the GeNOsys tablets into a product that could be manufactured in high quantities yet maintain the necessary tablet hardness, appropriate generated Nitric Oxide concentration and volume. Further, the completion of the contract with IriSys Pharmaceuticals represents a major milestone in the process toward submitting the company’s portable nitric oxide generator to the FDA. The work completed at IriSys was completed on time and under budget.

Clark Mower, director of GeNOsys, said: “We are moving rapidly toward a 510 (k) FDA approved device submission. We look forward to being able to customize the tablets for a specific disease, which represents a final step prior to FDA submission.”